Nexavar approved for liver cancer in China
This article was originally published in Scrip
Executive Summary
China's State FDA has approved Bayer Schering Pharma/Onyx Pharmaceuticals' Nexavar (sorafenib) for the treatment of non-resectable or metastatic hepatocellular carcinoma (HCC), extending the oral multi-targeted product's indications in what could become a large market.